Johnson Financial Group Inc. Sells 2,629 Shares of Amgen Inc. (NASDAQ:AMGN)

Johnson Financial Group Inc. lowered its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 21.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,472 shares of the medical research company's stock after selling 2,629 shares during the period. Johnson Financial Group Inc.'s holdings in Amgen were worth $2,703,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Centricity Wealth Management LLC bought a new position in Amgen in the 4th quarter worth approximately $25,000. Ritter Daniher Financial Advisory LLC DE raised its position in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after acquiring an additional 51 shares during the last quarter. Synergy Investment Management LLC bought a new stake in shares of Amgen during the 4th quarter valued at $34,000. Atala Financial Inc bought a new stake in shares of Amgen during the 4th quarter valued at $34,000. Finally, Heck Capital Advisors LLC bought a new stake in shares of Amgen during the 4th quarter valued at $36,000. Institutional investors own 76.50% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on AMGN shares. Cantor Fitzgerald started coverage on shares of Amgen in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 target price for the company. Piper Sandler Companies reiterated an "overweight" rating and set a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Wells Fargo & Company reiterated an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Piper Sandler boosted their price target on shares of Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Finally, Morgan Stanley boosted their price target on shares of Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a report on Wednesday, April 9th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $310.57.

Insider Buying and Selling

In related news, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by insiders.

Amgen Stock Up 1.9 %

Shares of NASDAQ:AMGN traded up $5.47 during trading on Tuesday, hitting $288.56. 2,147,355 shares of the company were exchanged, compared to its average volume of 2,786,646. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a market cap of $155.14 billion, a price-to-earnings ratio of 38.22, a P/E/G ratio of 2.63 and a beta of 0.59. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm has a fifty day moving average price of $301.29 and a two-hundred day moving average price of $292.11.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.30%. The ex-dividend date is Friday, May 16th. Amgen's payout ratio is presently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.